Keros Therapeutics (NASDAQ:KROS) Earns Neutral Rating from Wedbush

Wedbush reaffirmed their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS - Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. Wedbush currently has a $15.00 price objective on the stock.

Other equities analysts also recently issued research reports about the company. BTIG Research downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, December 12th. Wells Fargo & Company dropped their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, February 27th. Scotiabank reduced their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a report on Thursday, January 16th. William Blair downgraded shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 12th. Finally, Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Keros Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $42.33.

Remove Ads

Keros Therapeutics Trading Down 2.9 %

Shares of NASDAQ KROS traded down $0.30 during mid-day trading on Tuesday, reaching $9.98. The company had a trading volume of 1,544,444 shares, compared to its average volume of 718,431. The stock has a market cap of $404.81 million, a price-to-earnings ratio of -1.92 and a beta of 1.39. Keros Therapeutics has a 52 week low of $9.41 and a 52 week high of $72.37. The business's 50-day moving average is $11.00 and its 200-day moving average is $32.99.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. As a group, equities research analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Keros Therapeutics by 5.4% during the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after acquiring an additional 100,691 shares during the last quarter. Braidwell LP grew its position in Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock worth $29,989,000 after purchasing an additional 1,187,199 shares during the last quarter. Darwin Global Management Ltd. increased its stake in Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock valued at $26,707,000 after purchasing an additional 163,403 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock valued at $55,025,000 after purchasing an additional 577,220 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Keros Therapeutics by 53.3% in the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company's stock worth $13,901,000 after buying an additional 305,169 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.